Type 2 Diabetes Mellitus Flashcards

1
Q

Type 2 diabetes

A

A condition in which the combination of insulin resistance and beta-cell failure result in hyperglycaemia
Associated with obesity but not always
The resultant chronic hyperglycaemia may initially be managed by changes to diet / weight loss and may even be reversible
With time glucose lowering therapy including insulin, is needed

Traditionally thought to be a condition of late adulthood
Now good evidence that it can present throughout every decade of life
Increasing in all age groups but rapidly in early-adulthood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Stages of development of type 2 diabetes

A

Normal - fasting glucose less than 6mmol/L
Intermediate - impaired fasting glucose
Diabetes - more than 7mmol/L

Normal - 2-hr glucose (OGTT) < 7.7 mmol/L
Intermediate - Impaired glucose tolerance
Diabetes - more than 11 mmol/L

Normal - HbA1c less than 42mmol/mol
Intermediate - Pre-diabetes or non-diabetic hyperglycaemia
Diabetes - ≥ 48 mmol/mol

Normal - insulin resistance and production low
Intermediate - insulin resistance rising and production high
Diabetes - insulin resistance high and production low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Relative insulin deficiency in type 2 diabetes

A

Insulin is produced by pancreatic beta-cells but not enough to overcome insulin resistance
There is therefore a relative deficiency of insulin
This is important to understand as it explains why the hyperglycaemia encountered does not cause ketosis under ‘usual’ circumstances

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Long duration type 2 diabetes

A

In long-duration type 2 diabetes, beta-cell failure may progress to complete insulin deficiency
Usually on insulin at this point in any case, but important not to stop as at risk of ketoacidosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pathophysiology of type 2 diabetes

A

Genes and intrauterine environment and adult environment.
Insulin resistance and insulin secretion defects
Fatty acids important in pathogenesis and complications

HETEROGENOUS
People develop T2D at variable BMI, ages and progress differently

In type 2 diabetes, reduced insulin action causes less uptake of glucose into skeletal muscle
Hepatic glucose production is also increased due to both a reduction in insulin action and increase in glucagon action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

First Phase Insulin

A

Lost

No sharp peak after IV glucose challenge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Glucose not just from diet

A

Impaired insulin-mediated glucose disposal

Excessive glucagon-mediated glucose output

More glucose is put out the more glucose there already is

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Relationship between insulin resistance and insulin secretion

A

Inversely proportional

People developing type 2 diabetes have ‘fallen off the curve’
And for a given degree of insulin sensitivity secrete less insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Consequences of insulin resistance

A

Increased hepatic glucose production
Increased fatty acid uptake from gut in adipocyte - triglycerides form unhealthy types of lipids
Less skeletal muscle glucose uptake

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Genetics of type 2 diabetes

A

Single gene mutation ==> Diabetes (MODY)
‘Born with it, always going to develop diabetes’

Polymorphisms increasing risk of diabetes
‘Not born with it but high risk and may develop later depending on other factors’

Each individual SNP has only a mild effect on risk
Cumulative effect of all SNPs have a bigger effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the role of obesity?

A
Major risk factor for T2DM
Fatty acids and adipocytokines important
Central vs visceral obesity
80% T2DM are obese
Weight reduction useful treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Other associations

A

Perturbations in gut microbiota
Obesity, insulin resistance T2DM
Bacterial lipopolysaccharides fermentation to short chain FA, bacterial modulation bile acids
Inflammation, signaling metabolic pathways
Most studies correlative

Intra-uterine growth retardation
Hales et al 1991
Weight at age 1 year <8.16kg, 22% had type 2 diabetes of IGT
Weight age 1 year >12.25 kg, 6% had type 2 diabetes or IGT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Presentation of T2DM

A
Hyperglycaemia
Overweight
Dyslipidaemia
Fewer osmotic symptoms
With complications
Insulin resistance
Later insulin deficiency

Risk factors:
Age PCOS
High BMI Family Hx
Ethnicity Inactivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Diagnosis of type 2 diabetes

A

Osmotic symptoms
Infections
Screening test: incidental finding
at presentation of complication
Acute; hyperosmolar hyperglycaemic state,
Chronic; ischaemic heart disease, retinopathy

First line test for diagnosis is HbA1c.
1x HbA1c >=48mmol/L with symptoms
Or
2x HbA1c >=48 mmol/mol if aysymptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hyperosmolar hyperglycaemic state

A

Presents commonly with renal failure.
Insufficient insulin (NOT ABSENT) for prevention of hyperglycemia but sufficient insulin for suppression of lipolysis and ketogenesis.
Absence of significant acidosis.
Often identifiable precipitating event (infection, MI).

Unchecked gluconeogensis - hyperglycaemia
Osmotic diuresis - dehydration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management

A
Diet
Oral medication
Structured education
May need insulin later
Remission / reversal
Prevention diabetes-related complications and their risk factors:
Retinopathy			
Neuropathy				
Nephropathy				
Cardiovascular
17
Q

Principles of a T2DM consultation

A

Glycaemia: HbA1c, glucose monitoring if on insulin, medication review
Weight assessment
Blood pressure
Dyslipidaemia: cholesterol profile
Screening for complications: foot check, retinal screening

18
Q

Excess hepatic glucose production drug

A

Metformin

19
Q

Resistance to action of circulating insulin drug

A

Metformin

Thiozolidinediones

20
Q

Inadequate insulin production for extent of insulin resistance drug

A

Sulphonylureas
DPP4-inhibitors
GLP-1 Agonists

21
Q

Excess glucose in circulation drug

A

Alpha glucosidase inhibitor

SGLT-2 inhibitor

22
Q

Pioglitazone

A

Peroxisome proliferator-actived receptor agonists PPAR-γ
Pioglitazone
Insulin sensitizer, mainly peripheral
Adipocyte differentiation modified, weight gain but peripheral not central
Improvement in glycaemia and lipids
Evidence base on vascular outcomes
Side effects of older types hepatitis, heart failure

23
Q

Incretin effect

A

Oral glucose given - massive rise in insulin secretion - mediated by GLP 1

24
Q

Glucagon like peptide-1 (GLP-1)

A

Gut hormone
Secreted in response to nutrients in gut
Transcription product of pro-glucagon gene, mostly from L-cell
Stimulates insulin, suppresses glucagon
↑ satiety (feeling of ‘fullness’)
Short half life due to rapid degradation from enzyme dipeptidyl peptidase-4 (DPP4 inhibitor)
Used in treatment of diabetes mellitus

25
Q

Remission of T2DM (not cure)

A

Gastric bypass surgery has the potential to induce remission of type 2 diabetes

26
Q

Other aspects of management

A

Blood Pressure management
Hypertension very common in T2DM
Clear benefits for reduction esp with use of ACE-inhibitors

Lipid management
Total cholesterol raised
Triglycerides raised
HDL cholesterol reduced
Clear benefit to lipid-lowering therapy
27
Q

Present with kidney failure

A

Hyperosmotic hyperglycaemic state

28
Q

Insulin sensitiser

A

Pioglitazone

29
Q

Oral glucose - increased insulin

A

Incretin effect